Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States

被引:66
|
作者
Rosen, Jennifer B. [1 ,2 ]
Thomas, Ann R. [3 ]
Lexau, Catherine A. [4 ]
Reingold, Art [5 ]
Hadler, Jim L. [6 ]
Harrison, Lee H. [7 ]
Bennett, Nancy M. [8 ]
Schaffner, William [9 ]
Farley, Monica M. [10 ,11 ]
Beall, Bernard W. [1 ]
Moore, Matt R. [1 ]
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA USA
[2] Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA
[3] Oregon Publ Hlth Div, Portland, OR USA
[4] Minnesota Dept Hlth, St Paul, MN USA
[5] Calif Emerging Infect Program, Oakland, CA USA
[6] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA
[7] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[8] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, Rochester, NY USA
[9] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA
[10] Emory Univ, Dept Med, Sch Med, Georgia Emerging Infect Program, Atlanta, GA 30322 USA
[11] VA Med Ctr, Atlanta, GA USA
关键词
STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; CHANGING EPIDEMIOLOGY; SEROTYPE; CHILDREN; ERA; IMMUNIZATION; SURVEILLANCE; INFECTION; EMERGENCE;
D O I
10.1093/cid/cir326
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Rates of invasive pneumococcal disease (IPD) varied among the United States before pneumococcal conjugate vaccine (PCV7) introduction. We compared trends in IPD rates among diverse US sites over 10 years since PCV7 introduction. Methods. Patients with IPD of all ages were identified through active population and laboratory-based surveillance in 8 geographic areas under continuous surveillance during 1998-2009. Isolates were serotyped. IPD incidence rates and percent changes were calculated by site, serotype group, age, and year. Results. Reductions in rates of IPD ranged, by site, from 19 to 29.9 cases per 100,000 population during 1998-1999 to 11.2-18.0 cases per 100,000 population during 2009 (rate reduction, 5.1-15.3 cases per 100,000 population). Reductions in IPD rates among children aged < 5 years ranged from 35.7 to 117.2 cases per 100,000 population across the sites. Reductions in rates of IPD due to PCV7 serotypes were seen in all age groups at all sites, ranging from 12 to 21.4 cases per 100,000 population during 1998-1999 to < 2 cases per 100,000 population during 2009 (92%-98% reductions). Serotype 19A rates ranged from 0.4 to 1.5 cases per 100,000 population during 1998-1999 to 1.3 to 3.4 cases per 100,000 population during 2009 (rate difference, 0.9-2.8 cases per 100,000 population); modest increases were observed for most age groups across the sites. Rates of IPD due to all other serotypes ranged from 6.3 to 10.3 cases per 100,000 population during 1998-1999 to 8.3-13.6 cases per 100,000 population during 2009 (rate difference, -0.4 to 5.7 cases per 100,000 population). Across the sites, the greatest rate increases were seen in the 50-64 and > 65 year age groups. Conclusions. Reductions in IPD due to vaccine serotypes were consistent across sites. Changes in serotype 19A and all other serotypes were variable. Although relative increases in non-vaccine type serotypes were large in some sites, absolute rate increases were small.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [41] Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine
    Williams, Scott R.
    Mernagh, Paul J.
    Lee, Michael H. T.
    Tan, Jonathan T.
    MEDICAL JOURNAL OF AUSTRALIA, 2011, 194 (03) : 116 - 120
  • [42] Socioeconomic and Racial Disparities of Pediatric Invasive Pneumococcal Disease After the Introduction of the 7-valent Pneumococcal Conjugate Vaccine
    Spicer, Jennifer O.
    Thomas, Stephanie
    Holst, Amy
    Baughman, Wendy
    Farley, Monica M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (02) : 158 - 164
  • [43] Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use
    Baxter, Roger
    Aukes, Laurie
    Pelton, Stephen, I
    Yee, Arnold
    Klein, Nicola P.
    Gruber, William C.
    Scott, Daniel A.
    Center, Kimberly J.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (02) : 141 - 150
  • [44] Adult invasive pneumococcal disease pre- and peri-pneumococcal conjugate vaccine introduction in a tertiary hospital in Singapore
    Hsu, Li-Yang
    Lui, See Weng
    Lee, Jia Ling
    Hedzlyn, Hazwany Md Mahrom
    Kong, Debra Han-Lin
    Shameen, Suku
    Siti, Nur Puteri Mohammad
    Tan, Wei Yu
    Toh, Xin Yi
    Koh, Tse-Yuen
    Koh, Tse-Hsien
    JOURNAL OF MEDICAL MICROBIOLOGY, 2009, 58 (01) : 101 - 104
  • [45] Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine
    Aristegui, J.
    Bernaola, E.
    Pocheville, I.
    Garcia, C.
    Arranz, L.
    Duran, G.
    Perez, L.
    Bastida, M.
    Canduela, C.
    Aguirre, M. Herranz
    Garrote, E.
    Fletcher, M. A.
    Perez, C.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (05) : 303 - 310
  • [46] Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine
    J. Aristegui
    E. Bernaola
    I. Pocheville
    C. García
    L. Arranz
    G. Durán
    L. Pérez
    M. Bastida
    C. Canduela
    M. Herranz Aguirre
    E. Garrote
    M. A. Fletcher
    C. Pérez
    European Journal of Clinical Microbiology & Infectious Diseases, 2007, 26 : 303 - 310
  • [47] Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine
    Talbot, TR
    Poehling, KA
    Hartert, TV
    Arbogast, PG
    Halasa, NB
    Mitchel, E
    Schaffner, W
    Craig, AS
    Edwards, KM
    Griffin, MR
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) : 641 - 648
  • [48] Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain
    Camara, Jordi
    Maria Marimon, Jose
    Cercenado, Emilia
    Larrosa, Nieves
    Quesada, Maria Dolores
    Fontanals, Dionisia
    Cubero, Meritxell
    Perez-Trallero, Emilio
    Fenoll, Asuncion
    Linares, Josefina
    Ardanuy, Carmen
    PLOS ONE, 2017, 12 (04):
  • [49] Invasive Pneumococcal Disease in HIV-Infected Adults: Clinical Changes After the Introduction of the Pneumococcal Conjugate Vaccine in Children
    Burgos, Joaquin
    Penaranda, Maria
    Payeras, Antoni
    Villoslada, Aroa
    Curran, Adrian
    Garau, Margarita
    Riera, Melcior
    Crespo, Manuel
    Navarro, Jordi
    Van den Eynde, Eva
    Maria Planes, Ana
    Ribera, Esteban
    Pahissa, Albert
    Falco, Vicenc
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 (01) : 31 - 38
  • [50] Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)
    Artiles, Fernando
    Horcajada, Iballa
    Maria Canas, Ana
    Alamo, Isabel
    Bordes, Ana
    Gonzalez, Agustin
    Santana, Milagrosa
    Lafarga, Bernardo
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2009, 27 (01): : 14 - 21